Bausch Health Companies Inc. (FRA:BVF)
Germany · Delayed Price · Currency is EUR 4.471
-0.041 (-0.91%)
At close: Jan 29, 2026
Bausch Health Companies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 9,916 | 9,518 | 8,663 | 8,025 | 8,328 | 7,924 |
Other Revenue | 113 | 107 | 94 | 99 | 106 | 103 |
| 10,029 | 9,625 | 8,757 | 8,124 | 8,434 | 8,027 | |
Revenue Growth (YoY) | 5.86% | 9.91% | 7.79% | -3.68% | 5.07% | -6.67% |
Cost of Revenue | 2,942 | 2,782 | 2,559 | 2,364 | 2,394 | 2,249 |
Gross Profit | 7,087 | 6,843 | 6,198 | 5,760 | 6,040 | 5,778 |
Selling, General & Admin | 3,371 | 3,283 | 2,895 | 2,531 | 2,492 | 2,367 |
Research & Development | 631 | 616 | 604 | 529 | 465 | 452 |
Amortization of Goodwill & Intangibles | 1,024 | 1,077 | 1,077 | 1,215 | 1,375 | 1,645 |
Other Operating Expenses | - | - | 1 | 1 | - | 1 |
Operating Expenses | 5,026 | 4,976 | 4,577 | 4,276 | 4,332 | 4,465 |
Operating Income | 2,061 | 1,867 | 1,621 | 1,484 | 1,708 | 1,313 |
Interest Expense | -1,544 | -1,388 | -1,328 | -1,464 | -1,426 | -1,534 |
Interest & Investment Income | 48 | 33 | 26 | 14 | 7 | 13 |
Currency Exchange Gain (Loss) | -62 | -47 | -52 | -8 | 7 | -30 |
EBT Excluding Unusual Items | 503 | 465 | 267 | 26 | 296 | -238 |
Merger & Restructuring Charges | -62 | -36 | -95 | -68 | -73 | -23 |
Impairment of Goodwill | - | - | -493 | -824 | -469 | - |
Gain (Loss) on Sale of Assets | 6 | 10 | 3 | 5 | 2 | 1 |
Asset Writedown | -24 | -29 | -45 | -10 | -211 | -112 |
Legal Settlements | -45 | -220 | - | -9 | -356 | -422 |
Other Unusual Items | 252 | -5 | -80 | 752 | -205 | -107 |
Pretax Income | 520 | 167 | -390 | -129 | -1,024 | -934 |
Income Tax Expense | 199 | 239 | 221 | 83 | -87 | -375 |
Earnings From Continuing Operations | 321 | -72 | -611 | -212 | -937 | -559 |
Minority Interest in Earnings | 41 | 26 | 19 | -13 | -11 | -1 |
Net Income | 362 | -46 | -592 | -225 | -948 | -560 |
Net Income to Common | 362 | -46 | -592 | -225 | -948 | -560 |
Shares Outstanding (Basic) | 373 | 368 | 365 | 362 | 359 | 355 |
Shares Outstanding (Diluted) | 373 | 368 | 365 | 362 | 359 | 355 |
Shares Change (YoY) | 1.50% | 0.85% | 0.80% | 0.86% | 1.10% | 0.82% |
EPS (Basic) | 0.97 | -0.13 | -1.62 | -0.62 | -2.64 | -1.58 |
EPS (Diluted) | 0.97 | -0.13 | -1.62 | -0.62 | -2.64 | -1.58 |
Free Cash Flow | 1,095 | 1,260 | 817 | -946 | 1,157 | 809 |
Free Cash Flow Per Share | 2.94 | 3.42 | 2.24 | -2.61 | 3.22 | 2.28 |
Gross Margin | 70.67% | 71.10% | 70.78% | 70.90% | 71.61% | 71.98% |
Operating Margin | 20.55% | 19.40% | 18.51% | 18.27% | 20.25% | 16.36% |
Profit Margin | 3.61% | -0.48% | -6.76% | -2.77% | -11.24% | -6.98% |
Free Cash Flow Margin | 10.92% | 13.09% | 9.33% | -11.64% | 13.72% | 10.08% |
EBITDA | 3,286 | 3,134 | 2,885 | 2,878 | 3,260 | 3,138 |
EBITDA Margin | 32.77% | 32.56% | 32.95% | 35.43% | 38.65% | 39.09% |
D&A For EBITDA | 1,225 | 1,267 | 1,264 | 1,394 | 1,552 | 1,825 |
EBIT | 2,061 | 1,867 | 1,621 | 1,484 | 1,708 | 1,313 |
EBIT Margin | 20.55% | 19.40% | 18.51% | 18.27% | 20.25% | 16.36% |
Effective Tax Rate | 38.27% | 143.11% | - | - | - | - |
Revenue as Reported | 10,029 | 9,625 | 8,757 | 8,124 | 8,434 | 8,027 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.